Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Spanish Breast Cancer Research Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
Shattuck Labs, Inc.
Mural Oncology, Inc
AbbVie
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
EpicentRx, Inc.
North Eastern German Society of Gynaecological Oncology
Mayo Clinic
Pfizer
Astex Pharmaceuticals, Inc.
ImmunoGen, Inc.
M.D. Anderson Cancer Center
AstraZeneca
University of Nebraska
Pfizer
Spanish Breast Cancer Research Group
Rutgers, The State University of New Jersey
Spanish Breast Cancer Research Group
H. Lee Moffitt Cancer Center and Research Institute
Imunon
Ludwig Institute for Cancer Research
Dana-Farber Cancer Institute
Yale University
National Institutes of Health Clinical Center (CC)
SCRI Development Innovations, LLC
University of California, Davis
West Virginia University
National Cheng-Kung University Hospital
M.D. Anderson Cancer Center
ImmunoGen, Inc.
M.D. Anderson Cancer Center
Columbia University
University of California, San Francisco
University of California, San Francisco
PharmaMar
AstraZeneca
University of Louisville
Northwestern University
Eli Lilly and Company
Janssen Research & Development, LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)